Immunotherapy use outside clinical trial populations: never say never?

Rzeniewicz, K; Larkin, J; Menzies, A M; Turajlic, S

Rzeniewicz, K; Larkin, J; Menzies, A M; Turajlic, S.

Afiliación

Rzeniewicz K; Warwick Medical School, University of Warwick, Warwick, UK; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Larkin J; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK.
Menzies AM; Melanoma Institute Australia and The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia.
Turajlic S; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: samra.turajlic@crick.ac.uk.

Ann Oncol ; 32(7): 866-880, 2021 07.

Article en En | MEDLINE | ID: mdl-33771665

Asunto(s)

COVID-19; Neoplasias; Anciano; Niño; Humanos; Factores Inmunológicos; Inmunoterapia/efectos adversos; Neoplasias/terapia; SARS-CoV-2

Palabras clave

CTLA-4; PD-1; checkpoint inhibitors; immunotherapy; special populations

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Neoplasias Tipo de estudio: Guideline / Prognostic_studies Límite: Aged / Child / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google